Imatinib mesylate in chronic myeloid leukemia

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Chronic myeloid leukemia has become a paradigm for the discovery of target therapeutic approaches in the field of onco-hematology. Recognition of the tyrosine kinase activity of the p210Bcr-Abl oncoprotein led to the development of compounds targeting against BCR-ABL and then controlling the leukemic proliferation. Imatinib mesylate, one of the first tyrosine kinase inhibitors developed, was found effective and safe. According to five-years experience with this drug, it is recommended that the golden standard for initial treatment of newly diagnosis chronic myeloid leukemia patients should be 400 mg Imatinib daily. In this brief review, we discuss the current tools for the effective management of chronic myeloid leukemia with Imatinib, providing the updated results of IRIS and RIGHT clinical trials and then the suggestions how Imatinib-treated patients should be monitored.

Original languageEnglish
Pages (from-to)249-251
Number of pages3
JournalCurrent Stem Cell Research and Therapy
Volume2
Issue number3
DOIs
Publication statusPublished - Sep 2007

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Oncogene Proteins
Hematology
Clinical Trials
Imatinib Mesylate
Therapeutics
Pharmaceutical Preparations

Keywords

  • Abl
  • Molecular monitoring
  • Resistance
  • Treatment guidelines
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

Imatinib mesylate in chronic myeloid leukemia. / Carella, Angelo Michele; Lerma, Enrica.

In: Current Stem Cell Research and Therapy, Vol. 2, No. 3, 09.2007, p. 249-251.

Research output: Contribution to journalArticle

@article{b45ebb5c9c524d0b8d080709de488e94,
title = "Imatinib mesylate in chronic myeloid leukemia",
abstract = "Chronic myeloid leukemia has become a paradigm for the discovery of target therapeutic approaches in the field of onco-hematology. Recognition of the tyrosine kinase activity of the p210Bcr-Abl oncoprotein led to the development of compounds targeting against BCR-ABL and then controlling the leukemic proliferation. Imatinib mesylate, one of the first tyrosine kinase inhibitors developed, was found effective and safe. According to five-years experience with this drug, it is recommended that the golden standard for initial treatment of newly diagnosis chronic myeloid leukemia patients should be 400 mg Imatinib daily. In this brief review, we discuss the current tools for the effective management of chronic myeloid leukemia with Imatinib, providing the updated results of IRIS and RIGHT clinical trials and then the suggestions how Imatinib-treated patients should be monitored.",
keywords = "Abl, Molecular monitoring, Resistance, Treatment guidelines, Tyrosine kinase inhibitor",
author = "Carella, {Angelo Michele} and Enrica Lerma",
year = "2007",
month = "9",
doi = "10.2174/157488807781696276",
language = "English",
volume = "2",
pages = "249--251",
journal = "Current Stem Cell Research and Therapy",
issn = "1574-888X",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Imatinib mesylate in chronic myeloid leukemia

AU - Carella, Angelo Michele

AU - Lerma, Enrica

PY - 2007/9

Y1 - 2007/9

N2 - Chronic myeloid leukemia has become a paradigm for the discovery of target therapeutic approaches in the field of onco-hematology. Recognition of the tyrosine kinase activity of the p210Bcr-Abl oncoprotein led to the development of compounds targeting against BCR-ABL and then controlling the leukemic proliferation. Imatinib mesylate, one of the first tyrosine kinase inhibitors developed, was found effective and safe. According to five-years experience with this drug, it is recommended that the golden standard for initial treatment of newly diagnosis chronic myeloid leukemia patients should be 400 mg Imatinib daily. In this brief review, we discuss the current tools for the effective management of chronic myeloid leukemia with Imatinib, providing the updated results of IRIS and RIGHT clinical trials and then the suggestions how Imatinib-treated patients should be monitored.

AB - Chronic myeloid leukemia has become a paradigm for the discovery of target therapeutic approaches in the field of onco-hematology. Recognition of the tyrosine kinase activity of the p210Bcr-Abl oncoprotein led to the development of compounds targeting against BCR-ABL and then controlling the leukemic proliferation. Imatinib mesylate, one of the first tyrosine kinase inhibitors developed, was found effective and safe. According to five-years experience with this drug, it is recommended that the golden standard for initial treatment of newly diagnosis chronic myeloid leukemia patients should be 400 mg Imatinib daily. In this brief review, we discuss the current tools for the effective management of chronic myeloid leukemia with Imatinib, providing the updated results of IRIS and RIGHT clinical trials and then the suggestions how Imatinib-treated patients should be monitored.

KW - Abl

KW - Molecular monitoring

KW - Resistance

KW - Treatment guidelines

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=34848924266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848924266&partnerID=8YFLogxK

U2 - 10.2174/157488807781696276

DO - 10.2174/157488807781696276

M3 - Article

C2 - 18220908

AN - SCOPUS:34848924266

VL - 2

SP - 249

EP - 251

JO - Current Stem Cell Research and Therapy

JF - Current Stem Cell Research and Therapy

SN - 1574-888X

IS - 3

ER -